key: cord-0475035-84myq8bc
authors: Han, Larry; Wang, Xuan; Cai, Tianxi
title: On the Evaluation of Surrogate Markers in Real World Data Settings
date: 2021-04-12
journal: nan
DOI: nan
sha: 4d9c7d9f403b29ad040fcca6f446ec71a07da920
doc_id: 475035
cord_uid: 84myq8bc

Shortcomings of randomized clinical trials are pronounced in urgent health crises, when rapid identification of effective treatments is critical. Leveraging short-term surrogates in real-world data (RWD) can guide policymakers evaluating new treatments. In this paper, we develop novel estimators for the proportion of treatment effect (PTE) on the true outcome explained by a surrogate in RWD settings. We propose inverse probability weighted and doubly robust (DR) estimators of an optimal transformation of the surrogate and PTE by semi-nonparametrically modeling the relationship between the true outcome and surrogate given baseline covariates. We show that our estimators are consistent and asymptotically normal, and the DR estimator is consistent when either the propensity score model or outcome regression model is correctly specified. We compare our proposed estimators to existing estimators and show a reduction in bias and gains in efficiency through simulations. We illustrate the utility of our method in obtaining an interpretable PTE by conducting a cross-trial comparison of two biologic therapies for ulcerative colitis.

While randomized clinical trials (RCTs) remain the gold standard instrument for identifying efficacious and safe drugs (Concato, et al., 2000) , RCTs typically require long-term followup of patients to observe a sufficient number of events to estimate treatment effects and even then, the outcomes may be costly to measure (Bentley et al., 2019) . RCTs are also often limited to narrowly defined patient populations with results that are not always generalizable. These shortcomings are especially pronounced in urgent health crises and have led to increased interest in using real world data (RWD) and shorter term surrogate endpoints to efficiently and effectively evaluate treatments (Hernán & Robins, 2016; Corrigan-Curay et al., 2018; Hey et al., 2020; Gyawali et al., 2020) . For example, as multiple pharmaceutical companies pushed to develop vaccines and treatments for COVID-19 and to test them in RCTs (Lurie et al., 2020) , RWD from electronic health records (EHRs) have been collected at breakneck speed (Brat et al., 2020) .

The use of valid surrogate markers to infer treatment effects on long term outcomes has the potential to reduce trial cost and study duration (Ciani et al., 2017; Wickström & Moseley, 2017) . The explosion in recent years of RWD highlights an untapped opportunity to identify and validate surrogate markers. Since Prentice (1989) originally proposed a definition and operational criteria for identifying valid surrogate markers, many statistical methods have been developed to make inference about the proportion of treatment effect (PTE) explained by a surrogate in RCT settings Lin et al., 1997; Wang & Taylor, 2002; Parast et al., 2016; Price et al., 2018; Wang et al., 2020) . For example proposed a parametric model-based estimate assuming two regression models which rarely hold simultaneously (Lin et al., 1997) . Wang & Taylor (2002) proposed alternative measures of PTE that examined what the treatment effect would have been if the surrogate had the same distribution across treatment groups. Parast et al. (2016) proposed a fully nonparametric estimation procedure for the PTE defined in Wang & Taylor (2002) .

More recently, Wang et al. (2020) proposed an alternative non-parametric PTE estimator by identifying an optimal transformation of the surrogate S, g opt : S → g opt (S), such that g opt (S) optimally predicts Y . In addition to requiring weaker assumptions than those required by Parast et al. (2016) , this approach has the advantage of providing a direct approximation to the treatment effect on the outcome Y using the treatment effect on g opt (S).

These existing PTE estimates are derived for data from RCTs and not directly applicable to RWD where treatment assignment A may depend on confounding factors X. In this paper, we follow the strategy of Wang et al. (2020) to define PTE based on g opt and propose both IPW and doubly robust PTE estimators using RWD by semi-non-parametrically modeling the relationship between Y and S given X and imposing a propensity score (PS) model for A given X. We propose perturbation resampling methods for variance and confidence interval estimation. We establish the asymptotic properties of the proposed estimators, including double robustness of the proposed estimator in that it is consistent when either the PS model or the outcome regression (OR) models is correctly specified. Our simulation studies demonstrate that the proposed estimators and inference procedures perform well in finite samples. Finally, we illustrate the utility of our proposed procedures by conducting a crosstrial comparison of two biologic therapies for ulcerative colitis (UC).

Let Y be the primary outcome and S be the surrogate marker, both of which may be discrete or continuous. Throughout, the notation takes S to be continuous, but all derivations and theoretical results remain valid if S is discrete by replacing density functions with probability mass functions. We denote {Y (a) , S (a) } as the respective potential primary outcome and surrogate marker under treatment A = a, where A = 1 and A = 0 denote the treatment and the control group, respectively. With RWD, only

can be observed for an individual i, and the treatment assignment A i may depend on baseline confounding factors X i . For identifiability, we require the standard assumptions (Rubin, 2005; Imbens & Rubin, 2015) :

Assumption (1) states that within all covariate levels, patients may receive either treatment so that the PS is bounded away from 0 and 1. Assumption (2) implies that X includes all confounders that can affect the primary outcome and treatment simultaneously, or the surrogate and treatment simultaneously (Rubin, 2005; Imbens & Rubin, 2015) . We assume that the RWD for analysis consist of n independent and identically distributed random

.., n}.

The average treatment effect on Y is defined as:

and F(x) = P (X x). Without loss of generality, we assume that ∆ > 0. To approximate ∆ based on the treatment effect on S, Wang et al. (2020) identified a transformation function g opt (·) such that the treatment effect on the transformed surrogate, ∆ gopt = E[g opt (S (1) ) − g opt (S (0) )], can optimally predict ∆ in a certain sense. More formally, the optimality of g opt is with respect to minimizing the mean squared error

under the working assumption of (Y (1) , S (1) ) ⊥ (Y (0) , S (0) ). It was shown that g opt takes the form

and F a (s) = P (S (a) s). In addition, by employing the transformation g opt and defining the PTE of S as PTE gopt ≡ ∆ gopt /∆, Wang et al. (2020) showed that even if the working independence assumption does not hold, PTE gopt ∈ [0, 1] provided that

Assumptions (A1) and (A2) are weaker than those required in the literature to ensure that the PTE is between 0 and 1 and hence to avoid the surrogate paradox (VanderWeele, 2013).

Our goal here is to construct robust estimates for g opt and PTE gopt using RWD.

Estimation of g opt (s) and PTE gopt using RWD is more challenging than using RCT data because we cannot directly estimate m(s), λ, and P a (s) due to confounding. We propose an inverse probability weighted (IPW) estimator and a doubly robust (DR) estimator for g opt and PTE gopt accounting for the effects of X on A, Y and S. We first present the simpler IPW estimator and then the DR estimator. For both estimators, we impose a parametric model for π 1 (X), denoted by π 1 (X; α), where α is a finite dimensional parameter that can be estimated as the standard maximum likelihood estimator, α. A simple example is a logistic regression model π 1 (X; α) = G{α T Φ(X)}, where G(x) = e x /(1 + e x ) and Φ(X) is a vector of basis functions of X to account for potential non-linear effects.

To construct an IPW estimator for g opt , we first obtain IPW kernel smoothed estimators for m a (s) and f a (s) respectively as

is a symmetric density function and h = O(n −ν ) with ν ∈ (1/4, 1/2). Then m(·), P a (·) and λ may be estimated as

respectively. Subsequently, we construct plug-in estimators for g opt (s), ∆ gopt , ∆ and PTE gopt as

We show in Appendix 1 of the supplementary materials that when π 1 (x; α) is correctly specified, PTE g is consistent for PTE gopt . We also show that √ n( PTE g − PTE gopt ) converges in distribution to a normal distribution with mean 0 and variance σ 2 , where the form of σ 2 is given in the supplementary materials.

When the PS model is incorrectly specified, the IPW estimator is likely to be biased. Here, we propose augmented IPW estimators for g opt and PTE gopt to achieve improved robustness and efficiency. Following Robins et al. (1994) , for any counterfactual random variable U (a) , an augmented IPW estimator for its mean E(U (a) ) can be constructed as

where φ a (X i ) is an estimator for E(U To construct a DR estimator for g opt (s) = m(s) + λP 0 (s), we propose the following DR estimators for m a (s) and f a (s) respectively,

where ψ a,m (x) and ψ a,f (s; x) are the respective estimators for

and

In Appendix 2 of the supplementary materials, we show that m a,DR (s) and f a,DR (s) are consistent for m a (s) and f a (s) if either sup x | π a (x)−π a (x)| → 0 in probability or sup x,s {| ψ a,m (s; x)− ψ a,m (s; x)| + | ψ a,f (s; x) − ψ a,f (s; x)|} → 0 in probability.

To construct estimators ψ a,m (s; x) and ψ a,f (s; x), we impose flexible semi-non-parametric models for Y (a) | S (a) , X and S (a) | X to minimize assumptions on the dependency structure between S and Y . Specifically, we first impose a generalized regression model (GRM) (Han, 1987) for S i | A i = a, X i :

where D a (·) is an increasing function and H a (·, ·) is a strictly increasing function of each of its arguments, and the unknown covariate effects γ a = (γ a1 , ..., γ ap ) T are constrained to the unit sphere Ω : {γ : γ 2 = 1} for identifiability. With the given γ a under GRM and the no-unmeasured-confounders assumption, ψ a,f (s; x) can be estimated non-parametrically via kernel smoothing. To estimate γ a , Sherman (1993) showed that the maximum rank correlation estimator

is consistent and asymptotically normal for γ a . Subsequently, we estimate ψ a,f (s, x) as

.

To estimate ψ a,m (s; x), we impose a varying-coefficient generalized linear model (VGLM) (Hastie & Tibshirani, 1993) :

where M(·) is a known smooth link function, x = (1, x T ) T for any vector x and β a (s) is an unknown p + 1 dimensional unspecified smooth coefficient functions. We may estimate β a (s) as β a (s), the solution to

Then we estimate ψ a,m (s; x) as

These estimators (4) and (5) can then be plugged into (3b) and (3c) to construct f a,DR (s) and m a,DR (s) as in (3a).

Based on m a,DR (s) and f a,DR (s), we obtain a doubly robust estimator for g opt (s) as:

where m DR (s) = 1 a=0 m a,DR (s) P a,DR (s),

for a = 0, 1. We can now construct a plug-in estimator for ∆ gopt as ∆ g,DR = µ 1, g,DR − µ 0, g,DR ,

where µ a,g,DR = n −1

we estimate PTE gopt as PTE g,DR = ∆ g,DR / ∆ DR . Following similar arguments as given in Appendix 2 of the supplementary materials, it is not difficult to show that ∆ g,DR , ∆ DR and PTE g,DR are doubly robust estimators for ∆ gopt , ∆, and PTE gopt , respectively.

We propose to estimate the variability and construct confidence intervals of our proposed estimators using a perturbation-resampling approach (Jin et al., 2001; Tian et al., 2005) . For

.., B}, which are n×B independent and identically distributed non-negative random variables from a known distribution with unit mean and unit variance, such as the unit exponential distribution. For the IPW estimators,

where α * is obtained by fitting a weighted logistic regression

The perturbed counterparts of m(·),P a (·) and λ are obtained as

respectively. Subsequently, we construct the perturbed counterparts of g(s), ∆ gopt , ∆ and PTE as

For the DR estimators, for each set of V, we let

We construct the perturbed counterparts of g DR (s),∆ DR ,∆ g,DR , and PTE g,DR respectively as:

Operationally, we generate a large number, say B = 500, realizations for V and then obtain B realizations of the perturbed statistics of interest. Standard error estimates and confidence intervals can then be constructed based on empirical variances of these realizations.

We have conducted simulation studies to evaluate the finite sample performance of our proposed estimators compared to several existing methods. Namely, we considered the naive PTE estimator of , denoted PTE F,naive , which does not take into account baseline covariates X in the models Y | S, A and Y | A; a modified version that incorporates X into both models Y | S, A, X and Y | A, X, denoted PTE F,X ; a modified version that incorporates the propensity score into both models, denoted PTE F,IPW ; the PTE estimator given in Parast et al. (2016) , denoted PTE P ; and the PTE estimator of Wang et al. (2020) , denoted PTE W . We let n = 400 and 1000 and choose K(·) as a Gaussian kernel. To obtain the bandwidth h that satisfies the undersmoothing assumption, we set h = h opt n −c 0 , c 0 = 0.11

where h opt = 1.06n −1/5 as in Scott (2015). We compute the true population parameters via Monte Carlo, under the counterfactual models used to generate the data, with N = 100, 000 averaged over 100 replications. All results are summarized based on 500 simulated datasets for each configuration, and B = 500 resampling replications were used for variance and interval estimation based on the empirical variances.

We consider two general settings with a moderately strong surrogate in the first setting and a weak surrogate in the second setting. Specifically, in the first setting, we generate a

Gamma(2, 2) and X i3 ∼ Uniform(−1, 1), and

Under this setting, ∆ gopt = 0.29 and ∆ = 0.54 so that the true potential outcomes PTE is 0.537, i.e., S is a moderately strong surrogate for Y . We consider scenarios in which we correctly specify both the PS and OR models, misspecify the PS model by omitting the interaction term X 2 X 3 , misspecify the OR model by omitting the variable X 2 and all interaction terms including X 2 , and misspecify both models.

In the second setting, we consider a relatively weak surrogate generate data such that the effect of S on Y is non-linear. We generate baseline covariates [ Figure 1 about here.]

In Table 1 , we summarize results for PTE estimation obtained via the proposed method and other existing methods. When at least one of the PS and OR models are correctly specified, the DR estimator displays negligible bias and nominal coverage. The IPW estimator PTE g has substantial bias when the PS model is misspecified and the DR estimator also presents bias when both models are incorrect, as expected. In addition, the IPW estimator is less efficient compared to the DR estimator when the PS model is correctly specified. The estimate from PTE W , which assumes that treatment is randomly assigned, shows considerable bias and below nominal coverage. It is difficult to make a direct comparison of our estimators with other literature estimators, as they estimate slightly different P T E quantities, but it is useful to note that PTE F,X increases slightly from PTE F,naive toward the true P T E when baseline covariates are included correctly in the OR models Y | A, S, X and Y | A, X.

However, when the OR models are misspecified, PTE F,X shows substantial bias.

[ being close to 0. This is in part due to the nonmonotone relationship between Y and S and the fact that these estimators use S directly rather than g(S) in estimating the treatment effect.

[ Table 2 about here.]

Published randomized trials have shown that the partial Mayo score may be a good surrogate for the full Mayo score in assessing biologic therapies for ulcerative colitis (UC) (Lewis et al.,2008; Colombel et al., 2011; Ananthakrishnan et al., 2016) . The partial Mayo score is an inexpensive, non-invasive composite score that can be measured early and ranges from 0 to 9. It is based on a patient's self-assessed stool frequency (0-3), rectal bleeding (0-3), and a physician's global assessment (0-3). The full Mayo score ranges from 0 to 12 and consists of the partial Mayo score, in addition to an invasive endoscopoy score evaluating mucosal appearance (0-3), and is typically collected later in the trial. When conventional treatments fail, biologic therapies such as infliximab, adalimumab, or golimumab may be used (Rubin et al., 2019) . While these medications have been shown to be effective in placebo-controlled trials for rheumatoid arthritis , there has been a lack of trials comparing agents directly in UC. One of the first such trials, a phase 3b trial of vedolizumab vs. adalimumab for patients with moderate-to-severe UC, showed that vedolizumab was superior to adalimumab with respect to achievement of clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission (Sands et al., 2019) . The researchers were unable to postulate an explanation for the inconsistency of the results between the primary and secondary remission outcomes, and concluded that this question required further investigation.

To illustrate the utility of our proposed methods, we apply our procedure to examine the surrogacy of the partial Mayo score at week 6 on the primary outcome of the full Mayo score at week 54 among patients with moderate-to-severe UC. We examine an application of realworld interest in comparing head-to-head trials of two biologic therapies for patients with UC (Ungaro & Colombel, 2017) . Treatment randomization is broken by combining data from two separate trials on patients with active UC, one comparing infliximab against a placebo (NCT00036439) and another comparing golimumab against a placebo (NCT00488631). To adjust for confounding bias, we consider baseline covariates X including patient age, sex, race, and a health status score ranging from 0 to 100. Data was obtained from the Yale University Open Data Access (YODA) database (Ross et al., 2018) . The DR estimator for the treatment effect is estimated as ∆ = 2.326 in favor of golimumab and the corresponding treatment effect on the predicted outcome ∆ gopt is estimated to be ∆ g,DR = 2.031. This results in a DR PTE estimate of 0.872 with a 95% CI of (0.741, 1.003),

suggesting that the partial Mayo score at week 6 is a strong surrogate for the full Mayo score at week 54. The results for the IPW PTE estimate is very similar at 0.878 with a 95% CI of (0.728, 1.029).

There is great interest in leveraging RWD, including EHRs, registry data, and cross-trial data, to inform the design of shorter and cheaper clinical trials through surrogate marker validation. We propose the first IPW and DR estimators for the PTE explained by a surrogate marker when treatment is not randomly assigned. We generalize the approach detailed in Wang et al. (2020) for RCT data to RWD in the presence of treatment by indication bias. Our proposed doubly robust estimator is efficient and consistent when at least one of the PS and OR models is correctly specified. In the case of UC, we have validated a partial Mayo score at week 6, which does not require an invasive endoscopy procedure, as a strong surrogate for the full Mayo score at week 54 in a cross-trial study, supplementing evidence from previous placebo-controlled trials (Lewis et al., 2008; Colombel et al., 2011; Ananthakrishnan et al., 2016) . This finding may be particularly useful in informing future cross-trial designs for biologic therapies.

To provide flexibility in the estimation of g opt (·) and P T E, we use a varying-coefficient

i , X i . We are able to handle multiple confounders by implementing a two-step estimator that first reduces potentially highdimensional X into X Tγ a through the generalized regression model and then estimates the conditional density of S | X Tγ a using the method of Hall et al. (2004) . This procedure may be computationally intensive, and in the case when the researcher is confident in the specification of the PS model, it may be advisable to consider the IPW estimation procedure.

Our approach has some limitations. First, our proposed plug-in estimators for PTE use the same data to estimate both g opt and PTE given g, which may result in overfitting bias.

However, in simulation studies, the bias appears small compared to the standard error, even with modest sample sizes. For small sample sizes, cross-validation may be needed, in which separate data is used to estimate g opt and PTE given g. Second, our approach relies on a few assumptions, the strongest of which is the working independence assumption (Y (1) , S (1) ) ⊥ (Y (0) , S (0) ) needed for deriving the form of g opt . This assumption has been discussed extensively in Wang et al. (2020) . Here, we reiterate that the assumption is only a working assumption that allows for derivation of the specific form of g opt (·) and

is not required for valid inference. When the working independence assumption is severely violated, our proposed g opt can still be considered an optimal transformation of the surrogate marker for the difference in the primary outcome for two independent patients, one in the treatment group and the other in the control group. Third, we fit our PS models using logistic regression with specified basis functions, but alternative approaches like gradient boosting, super learner, and other machine learning classifiers may be considered in future research (Parast & Griffin, 2017) . 

Throughout, we assume that all components of (Y, S, A, X) are sub-gaussian, the true conditional mean function ψ † a,m (s; x) = E(Y (a) | S (a) = s, X = x) and the true conditional density of S (a) | X = x, ψ † a,f (s; x), are continuously differentiable. We also assume that S (a) has a finite support and that h = O(n −ν ) with ν ∈ (1/4, 1/2). In this section, we show that when the propensity score model is correctly specified, the proposed IPW kernel smoothed estimators g(s) and PTE g are consistent for g opt (s) and PTE gopt , respectively. We will also show that √ n( PTE g − PTE gopt ) converges in distribution to a normal distribution with mean zero and variance σ 2 , which we will derive. To this end, we first show that m a (s) and f a (s) are consistent for m a (s) and f a (s), respectively. Without loss of generality, we prove the

.

First, under the correct specification of the PS model, α → α 0 in probability, where α 0 is the true parameter value. Hence max i | ω ai − ω ai | sup x |π a (x; α) −1 − π a (x; α 0 ) −1 | → 0 in probability, where ω ai = I(A i = a)/π a (X i ; α 0 ). It then follows from standard theory for non-parametric kernel estimators (Masry, 1996; Pagan & Ullah, 1999) and Taylor series expansions that

where m ′ a (s; α) = ∂ m a (s; α)/∂α and c is any small constant. Similarly, we have sup

It follows from the uniform convergence of g(s) → g opt (s) and D(s) → D(s) = P (S (1) s) − P (S (0) s) that ∆ g − ∆ gopt → 0 in probability. This, together with the consistency of ∆ for ∆, implies the consistency of PTE g for PTE gopt .

We next establish the asymptotic normality of √ n( PTE g − PTE gopt ). First, note that 

Similarly, we have

Since λ = µ 0 − µ m0 µ P 0 0 and λ = µ 0 − µ m0 µ P 0 0 , it follows from above that

Gathering the above expansions, we may obtain the form of g(s) − g opt (s) as

To derive the asymptotic distribution for PTE, observe that

Therefore, by the central limit theorem, √ n PTE − PTE converges in distribution to a normal with mean zero and variance

under the correct specification of the PS model, sup s | m a,DR (s) − m a (s)| + sup s | f a,DR (s) − f a (s)| → 0 in probability.

We next establish the consistency of the DR estimators when the PS model may be misspecified but the OR models are correctly specified. First consider f a,DR (s), which can be written as

where ε a,f (s; D i ) = {K h (S i − s) − ψ † a,f (s; X i )}ω ai . It follows from the uniform convergence of kernel smoothed estimators (Pagan & Ullah, 1999) that

and

E{ε a,DR (s; 

and ε a,m (s;

and ω ai →ω ai , we arrive at the consistency of m a,DR (s) to m a (s) when the PS model may be mis-specified but the OR models are correctly specified.

Thus, we get the double robustness properties for f a,DR (s) and m a,DR (s).

Since all remaining estimators relevant to g DR (s) are plug-in estimators that are derived based on m a,DR (s) and f a,DR (s), we can conclude the double robustness of g DR (s) for g opt (s).

Finally, the PTE will be doubly robust by standard arguments for the conditional mean estimators (Robins et al., 1994) , where we construct a plug-in estimator for ∆ gopt as ∆ g,DR = µ 1, g,DR − µ 0, g,DR , where µ a,g,DR = n −1

and n a = n i=1 I(A i = a), a = 0, 1. Similarly, we define ∆ DR = µ 1,DR − µ 0,DR , where µ a,DR = n −1 Partial Mayo Score at Week 6 (s) Estimated g(s) Figure 2 : Estimated g(s) based on IPW (red) and DR (black) estimators and pointwise 95% confidence intervals for the partial Mayo score at week 6 (surrogate) in a cross-trial comparison of infliximab and golimumab for 361 UC patients 

Comparative effectiveness of infliximab and adalimumab in crohn's disease and ulcerative colitis

Conducting clinical trials-costs, impacts, and the value of clinical trials networks: a scoping review

Time to review the role of surrogate end points in health policy: state of the art and the way forward

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis

Randomized, controlled trials, observational studies, and the hierarchy of research designs

Real-world evidence and real-world data for evaluating drug safety and effectiveness

Statistical validation of intermediate endpoints for chronic diseases

Sample size for studying intermediate endpoints within intervention trials or observational studies

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs

Cross-validation and the estimation of conditional probability densities

Non-parametric analysis of a generalized regression model: the maximum rank correlation estimator

Varying-coefficient models

Using big data to emulate a target trial when a randomized trial is not available

US Food and Drug Administration recommendations on the use of surrogate measures as end points in new anti-infective drug approvals

Causal inference in statistics, social, and biomedical sciences

A simple resampling method by perturbing the minimand

Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis

Estimating the proportion of treatment effect explained by a surrogate marker

Developing Covid-19 vaccines at pandemic speed

Multivariate local polynomial regression for time series: uniform strong consistency and rates

Nonparametric econometrics

Landmark estimation of survival and treatment effects in observational studies

Robust estimation of the proportion of treatment effect explained by surrogate marker information

Surrogate endpoints in clinical trials: definition and operational criteria

Estimation of the optimal surrogate based on a randomized trial

Estimation of regression coefficients when some regressors are not always observed

Overview and experience of the YODA Project with clinical trial data sharing after 5 years. Scientific data

Causal inference using potential outcomes: Design, modeling, decisions

ACG clinical guideline: ulcerative colitis in adults

Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis

Multivariate density estimation: theory, practice, and visualization

The limiting distribution of the maximum rank correlation estimator

Baricitinib versus placebo or adalimumab in rheumatoid arthritis

On the Cox model with time-varying regression coefficients

Biologics in inflammatory bowel disease-time for direct comparisons. Alimentary pharmacology & therapeutics

Surrogate measures and consistent surrogates

Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker

In this section, we prove that our proposed DR estimators are consistent when either the PS model or the OR models are correctly specified. Recall that we proposed the augmented IPW estimators for m a (s) and f a (s),and ψ a,f (s; x) are estimators for the conditional mean ψ † a,m (s; x) and the conditional density ψ † a,f (s; x), respectively.We now show that the estimators are consistent if either supLetᾱ,ψ a,m (s; x),ψ a,f (s; x) denote the respective limits of α, ψ a,m (s; x) and ψ a,f (s; x) under possible mis-specification of their respective models,π a (x) = π a (x;ᾱ), andω ai = I(A i = a)/π a (X i ). Regardless of the adequacy of the models, by the central limit theorem and convergence of kernel smoothed estimators (Pagan & Ullah, 1999) , we have that α −ᾱ = O p (n − 1 2 ) and sup s,in probability as shown in Appendix 1. In addition, the augmentation terms(ω ai − 1)ψ a,f (s; X i ) + O p ( α − α 0 2 ) also converge to 0 in probability, regardless of the adequacy of the OR models. Therefore,